USP site in China
This article was originally published in The Tan Sheet
Executive Summary
U.S. Pharmacopeia's newest international site in Shanghai will enable the organization to work with Chinese regulators and manufacturers to ensure the safety of dietary supplements, pharmaceuticals and food ingredients, USP states in a Sept. 6 release. The opening of the site was celebrated with a ribbon-cutting ceremony Sept. 8, which was attended by USP executives as well as State Food and Drug Administration officials, among others. "USP-China will work closely with SFDA, the Chinese Pharmacopeia Commission, [the National Institute for the control of Pharmaceutical and Biological Products] and other constituencies to help ensure the quality of medicines and food ingredients," USP says. "Our presence will benefit Chinese manufacturers, government agencies and ultimately patients in China, U.S. and the many countries to which China exports," organization adds. SFDA recently announced it was planning to spend 8.8 bil. yuan ($1.1 bil.) over the next three to five years to strengthen food and drug oversight and infrastructure (1"The Tan Sheet" Aug. 27, 2007, In Brief)...
You may also be interested in...
China food safety efforts
China will spend 8.8 bil. yuan ($1.1 bil.) during the next three to five years to strengthen food and drug oversight and infrastructure, China's State Food and Drug Administration Spokeswoman Yan Jiangying said during a press conference in Beijing Aug. 8. Approximately 6.3 bil. yuan ($790 mil.) will be funded by the central government for initiatives in Western and Central China, while the rest will come from local governments in Eastern China, she added. On May 24, SFDA announced the "2007 National Plan of Special Rectification of Food Safety" to improve the safety of food eaten in China and exported food (1"The Tan Sheet" June 4, 2007, p. 12). In other safety news, Yan noted SFDA has released a list of Web sites that may legally sell drugs online, including four retail sites authorized to sell nonprescription drugs to consumers...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.